title: HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy.
abstract: HIV-associated pityriasis rubra pilaris (PRP) or PRP type VI designates a new distinctive entity reported in HIV patients. It is characterized by cutaneous lesions of PRP and variable association with lesions of acne conglobata, hidradenitis suppurativa and lichen spinulosus. We report a patient with HIV-associated PRP which was treated by triple antiretroviral therapy (zidovudine, lamivudin and saquinavir) with complete response. The patient has remained free from symptoms for 20 months of follow-up. We review the clinical features, pathology, evolution, treatment and possible aetiology of this recently described entity.
authors.affiliation: Departments of Dermatology, Río Hortega University Hospital, Valladolid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: González-López
authors.forename: E
authors.initials: E
authors.lastname: Velasco
authors.forename: T
authors.initials: T
authors.lastname: Pozo
authors.forename: A
authors.initials: A
authors.lastname: Del Villar
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D005260:Female; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D010916:Pityriasis Rubra Pilaris / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D019258:Saquinavir / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019258:Saquinavir